Northern Ireland Cancer Centre, Belfast, United Kingdom.
The Christie NHS Foundation Trust, Manchester, United Kingdom.
JCO Clin Cancer Inform. 2023 Apr;7:e2200150. doi: 10.1200/CCI.22.00150.
The Christie NHS Foundation Trust launched their electronic patient-reported outcome measures (ePROMs) service in January 2019 in the routine clinical setting. The lung cancer questionnaires consist of 14 symptom items, adapted from the Common Terminology Criteria for Adverse Events (version 5.0) and the EuroQol EQ-5D-5L quality-of-life (QoL) tool. Patients with lung cancer are invited to complete questionnaires assessing their symptoms and QoL using an online platform.
The ePROM responses and clinical, pathologic, and treatment data for patients who completed the questionnaires between January 2019 and December 2020 were extracted from electronic medical records. The symptom and QoL scores of patients who completed baseline pretreatment ePROMs and also those who completed ePROMs pre- and postpalliative lung systemic anticancer therapy (SACT) or radical thoracic radiotherapy were evaluated. Pretreatment questionnaires were analyzed according to age, Eastern Cooperative Oncology Group performance status (ECOG PS), and Adult Comorbidity Evaluation-27 (ACE-27) comorbidity score.
One thousand four hundred eighty patients with lung cancer were included. There were no statistically significant differences in symptoms and QoL scores between age groups. Cough ( = .006) and EQ-5D-5L mobility scores ( = .006) were significantly worse for patients with an ECOG PS of 0-1. Dyspnea ( = .035), hemoptysis ( = .023), nausea ( = .041), mobility ( = .004), and self-care ( = .0420) were significantly worse for those with higher ACE-27 scores (2-3 0-1). Palliative SACT was associated with a significant improvement in cough ( < .001) and hemoptysis ( = .025), but significantly negatively affected mobility ( = .013). Patients receiving radical thoracic radiotherapy reported a significant improvement in hemoptysis ( = .042) but worse pain ( = .002) and fatigue ( = .01). Other changes in symptom and QoL scores were not significant.
The symptoms and QoL reported at baseline and before and after both palliative SACT and radical thoracic radiotherapy are clinically relevant and meaningful. We have demonstrated that routine implementation of ePROMs into clinical practice is feasible and can inform clinical practice and future research.
克里斯蒂 NHS 基金会信托基金于 2019 年 1 月在常规临床环境中推出了电子患者报告结局测量(ePROMs)服务。肺癌问卷包括 14 个症状项目,改编自不良事件通用术语标准(版本 5.0)和欧洲五维健康量表(EQ-5D-5L)生活质量(QoL)工具。邀请肺癌患者使用在线平台完成评估其症状和 QoL 的问卷。
从电子病历中提取 2019 年 1 月至 2020 年 12 月期间完成问卷的患者的 ePROM 回复以及临床、病理和治疗数据。评估完成基线预处理 ePROM 以及姑息性肺癌全身抗癌治疗(SACT)或根治性胸部放疗前后完成 ePROM 的患者的症状和 QoL 评分。根据年龄、东部合作肿瘤学组表现状态(ECOG PS)和成人合并症评估-27(ACE-27)合并症评分分析预处理问卷。
共纳入 1480 例肺癌患者。各年龄段患者的症状和 QoL 评分无统计学差异。ECOG PS 为 0-1 的患者咳嗽( =.006)和 EQ-5D-5L 活动能力评分( =.006)明显更差。呼吸困难( =.035)、咯血( =.023)、恶心( =.041)、活动能力( =.004)和自我护理( =.0420)评分较高的患者(2-3 0-1)明显更差。姑息性 SACT 与咳嗽(<.001)和咯血( =.025)显著改善相关,但显著影响活动能力( =.013)。接受根治性胸部放疗的患者报告咯血明显改善( =.042),但疼痛( =.002)和疲劳( =.01)更差。症状和 QoL 评分的其他变化不显著。
姑息性 SACT 和根治性胸部放疗前后报告的基线和基线时的症状和 QoL 具有临床意义和重要意义。我们已经证明,将 ePROM 常规实施到临床实践中是可行的,并可以为临床实践和未来研究提供信息。